Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 37Carcinoma, Non-Small-Cell Lung 34Multiple Myeloma 32Recurrence 29Prostatic Neoplasms 28Melanoma 21Leukemia, Myeloid, Acute 21Breast Neoplasms 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Glioblastoma 15Pancreatic Neoplasms 14Sarcoma 13Neuroblastoma 13Lymphoma 13Glioma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia 10Ovarian Neoplasms 9Lung Neoplasms 9Colorectal Neoplasms 9Carcinoma, Hepatocellular 9Small Cell Lung Carcinoma 8Lymphoma, Large B-Cell, Diffuse 8Lambert-Eaton Myasthenic Syndrome 8Pheochromocytoma 7Neuroendocrine Tumors 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Gastrointestinal Stromal Tumors 7Carcinoma, Renal Cell 7

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × PSR Ovarian Cancer With a BRCA Mutation × Clear all
NCT03063710 2018-05-17

Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

AstraZeneca

No longer available
Gynecologic

PSR Ovarian Cancer With a BRCA Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡